EBIT: Income before interest and taxes.
Acrivon Therapeutics, Inc. (ACRV) had EBIT of $-22.65M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-21.01M |
|
-- |
|
-- |
|
$22.65M |
|
$-22.65M |
|
$1.64M |
|
$-21.01M |
|
$-21.01M |
|
$-21.01M |
|
$-21.01M |
|
$-21.01M |
|
$-21.01M |
|
|
EBIT |
$-22.65M |
$-22.49M |
|
38.46M |
|
38.46M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$138.41M |
|
$5.07M |
|
$20.17M |
|
$158.58M |
|
$13.43M |
|
-- |
|
$2.12M |
|
$15.55M |
|
$143.04M |
|
$143.04M |
|
$143.04M |
|
31.45M |
|
| Cash Flow Statement Financials | |
$-36.15M |
|
$38.66M |
|
$-0.44M |
|
$40.02M |
|
$42.10M |
|
$2.08M |
|
$7.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.31 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-36.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.69% |
|
-14.69% |
|
-13.25% |
|
-14.69% |
|
$4.55 |
|
$-0.95 |
|
$-0.94 |
|